As someone has has in the past worked in biotechnology software and is currently working on biothech instrumentation software - you are EXACTLY correct.<p>The problem with #2 is that we could get a lot of things cheaper and faster to market with only slightly more risk for the consumer. But the regulators have no incentive to take on that extra bit of risk. Sick people on the other hand...